Kyle Doherty

An increased focus on long-term and genomic analyses on established treatments in prostate cancer have revealed new opportunities for patients across disease states.

The investigational CAR T-cell therapy GD2-CART01 showed preliminary antitumor activity and safety in pediatric patients with relapsed or refractory high-risk neuroblastoma, according to data from a phase 1/2 trial.

Perioperative toripalimab plus chemotherapy generated a median event-free survival benefit vs placebo plus chemotherapy in patients with resectable stage III non–small cell lung cancer.

Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

In an 11-to-1 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the proposed indication of olaparib in combination with abiraterone acetate and prednisone or prednisolone for the initial treatment of patients with metastatic castration-resistant prostate cancer should be restricted to those whose tumors harbor a BRCA mutation.

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.

Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.

A deep learning risk prediction model was able to accurately identify patients with endometrial cancer at low and high risk of distant recurrence, according to data presented during the 2023 AACR Annual Meeting.

The investigational tetravalent bispecific antibody AFM13 displayed clinical efficacy in heavily pretreated patients with CD30-positive relapsed/refractory peripheral T-cell lymphoma.

The National Institute for Health and Care Excellence announced final draft guidance recommending the PARP inhibitor olaparib for patients with HER2-negative, high-risk early breast cancer harboring a BRCA1/2 mutation, as well as for those with previously treated hormone-relapsed metastatic prostate cancer with a BRCA1/2 mutation.

CAR T-cell therapies have transformed the treatment landscape of multiple hematologic malignancies since they first rose to prominence, but they are associated with a high financial cost, both for the patient and the health care institution that provides them.

Elias Jabbour, MD; Harry Paul Erba, MD, PhD; Anjali Advani, MD; and Sameem Abedin, MD, discuss key updates pertaining to the leukemia treatment landscape that were presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Because of the disease’s rarity relative to other hematologic malignancies and challenges arriving at an accurate diagnosis, patients with blastic plasmacytoid dendritic cell neoplasm have historically encountered a dearth of effective treatment options.

The first-in-class telomerase inhibitor imetelstat is poised to expand the myelofibrosis treatment armamentarium should it prove safe and effective in the newly initiated phase 3 IMpactMF trial.

Although some patients with stage II/III colorectal cancer were at an increased risk of severe symptoms and deterioration over time, patient-reported symptoms showed that those with newly diagnosed disease generally reported a low symptom burden that remained stable or improved after receiving adjuvant systemic therapy, according to a retrospective analysis.

Roadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

Despite incremental advances in the treatment landscape of metastatic colorectal cancer, patients with the disease still face a poor prognosis.

Clinicians tasked with treating patients with non–small cell lung cancer may soon be gaining an additional therapeutic target, this one directed at CEACAM5.

Findings from several large phase 3 studies along with continued development of emerging therapies promise to alter the treatment landscape for patients with myelodysplastic syndromes.

Melissa L. Pilewskie, MD, highlightes some of the primary components of her presentation concerning high-risk breast lesions, which will be delivered during the 40th Annual Miami Breast Cancer Conference®

As artificial intelligence in cancer care continues to be better understood and refined, the number of potential clinical applications is rapidly expanding.

Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.

Matthew Rettig, MD, discusses emerging treatment options for patients with stage IV metastatic prostate cancer and highlights key data from clinical trials in the space.

Patients with relapsed or refractory multiple myeloma treated with the CAR T-cell agent idecabtagene vicleucel had comparable efficacy and safety outcomes regardless of whether they had renal impairment, according to findings from a real-world study.

As more agents are evaluated either in addition to or following PD-1/PD-L1 inhibitors, more information may be learned about how best to leverage alternate biomarkers, according to Marina C. Garassino, MD.

Patients with HER2-overexpressing metastatic or advanced gastric/gastroesophageal junction adenocarcinoma treated with HER-Vaxx plus standard-of-care chemotherapy had a statistically significant survival benefit compared with those who received chemotherapy alone.

Leading experts in the field of liver cancer contextualized how recent data are influencing the treatment paradigm in hepatocellular carcinoma.

The biomarker claudin 18.2 has recently shown promise as an intriguing new target in the gastroesophageal junction adenocarcinoma space.

Michelle Shiller, DO, AP/CP, MGP, discusses the evolving role of HER2 as a biomarker for the treatment of patients with breast cancer and the impact of findings from the DESTINY-Breast02, DESTINY-Breast03, and DESTINY-Breast04 trials on the HER2 testing landscape.